<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707729</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)454/2020</org_study_id>
    <nct_id>NCT04707729</nct_id>
  </id_info>
  <brief_title>ROX Index for the Timing of Intubation in Nasal High Flow</brief_title>
  <acronym>ROX-1</acronym>
  <official_title>ROX Index Compared to Standard of Care for the Timing of Intubation in Patients Supported by Nasal High Flow: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late or delayed intubation in patients with acute hypoxemic respiratory failure (AHRF)&#xD;
      treated with nasal high flow (NHF) is associated with increased patient mortality. The ROX&#xD;
      index has been designed and validated to predict outcome of NFH therapy by identifying those&#xD;
      patients with a high risk of NHF failure and those with a high probability of success.&#xD;
      Whether or not the ROX index may improve patient outcome remains to be shown. To do so, a&#xD;
      strategy using the ROX index must lead to earlier intubation than commonly-used criteria.&#xD;
&#xD;
      The objective of the ROX-1 trial is to assess whether the use of an algorithm incorporating&#xD;
      the ROX index to standard of care for the time to intubation in patients with AHRF supported&#xD;
      with NHF isassociated with an increase in the proportion of patients who are intubated within&#xD;
      the first 12 hours among those patients who fail on NHF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The ROX-1 trial is an international, multicenter, parallel, open-label randomized controlled two-arm trial that will be performed in patients with AHRF, supported by nasal high flow, who are admitted to the intensive care unit (ICU).&#xD;
Patients will be randomized after stratification according to PaO2/FiO2, through an online automatic centralized and computerized system to one of the study groups (1:1 ratio): traditional intubation criteria or traditional intubation criteria + ROX criteria.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early intubation</measure>
    <time_frame>12 hours since HFNC onset</time_frame>
    <description>Proportion of patients who will be intubated in the first 12 hours after inclusion between the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intubation rate</measure>
    <time_frame>Through ICU length of stay, an average of 30 days</time_frame>
    <description>Rate of total intubations (early plus late)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality within the first 28 days since randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Through ICU length of stay, an average of 30 days</time_frame>
    <description>Mortality in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Through hospital length of stay, an average of 45 days</time_frame>
    <description>Mortality in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days within the first 28 days</measure>
    <time_frame>28 days since the intubation</time_frame>
    <description>Days free of mechanical ventilation in the first 28 days in those patients who needed to be intubated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue treatments</measure>
    <time_frame>Through ICU length of stay, an average of 30 days</time_frame>
    <description>Need for rescue therapies for refractory hypoxemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for tracheotomy</measure>
    <time_frame>Through ICU length of stay, an average of 30 days</time_frame>
    <description>Need for tracheotomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Through ICU length of stay, an average of 30 days</time_frame>
    <description>Days admitted in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Through hospital length of stay, an average of 45 days</time_frame>
    <description>Days admitted in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications during tracheal intubation</measure>
    <time_frame>Through ICU length of stay, an average of 30 days</time_frame>
    <description>Proportion of complications that appear during endotracheal intubation in those patients who fail</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">630</enrollment>
  <condition>Acute Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be intubated according to both the standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care + ROX algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the intervention arm, patients will be intubated according to both the standard of care and the ROX index, whichever are met first. If the patient has a ROX index below different thresholds after different time-point within the first 12 hours since randomization, the NHF support will be increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. Then, the ROX index will be recalculated in 30 minutes. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done, the ROX index will be recalculated after 30 minutes of full NHF support. Then: 1) if the ΔROX is &lt;0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 30 minutes; and 3) if the ΔROX is &gt;0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ROX index algorithm</intervention_name>
    <description>The thresholds of the ROX index for intubation are the following:&#xD;
After 2 hours of HFNC: ROX &lt;2.85.&#xD;
After 4 and 6 hours of HFNC: ROX &lt;3.47&#xD;
After 8, 10 and 12 hours of HFNC: ROX &lt;3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is &lt;0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is &gt;0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.</description>
    <arm_group_label>Standard of care + ROX algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All consecutive patients older than 18 years with acute hypoxemic respiratory failure&#xD;
             who need to be supported with nasal high flow (NHF) will be considered for inclusion.&#xD;
&#xD;
               -  Criteria for initiation of NHF if they had a respiratory rate &gt; 25 breaths/min&#xD;
                  and/or pulse oximetry (SpO2) &lt; 92% while receiving standard oxygen administered&#xD;
                  through a facemask at 10 L/mn or more.&#xD;
&#xD;
               -  Patients already treated with NHF for acute respiratory failure prior to ICU&#xD;
                  admission will be enrolled if duration of NHF prior to randomization does not&#xD;
                  exceed one hour.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years old.&#xD;
&#xD;
          -  Patients with indication for immediate intubation.&#xD;
&#xD;
          -  Patients treated with NHF for more than 1h prior to randomization.&#xD;
&#xD;
          -  Patients with do-not-intubate order.&#xD;
&#xD;
          -  Patients electively intubated for diagnostic or therapeutic procedures.&#xD;
             (fibrobronchoscopy, surgery).&#xD;
&#xD;
          -  Patients with no pulmonary infiltrates on chest X-ray&#xD;
&#xD;
          -  Patient with post-extubation AHRF.&#xD;
&#xD;
          -  Awake ECMO.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Refusal to participate or participation in another interventional study with the same&#xD;
             primary outcome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oriol Roca, MD PhD</last_name>
    <phone>+34932746209</phone>
    <email>oroca@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Pacheco, MD</last_name>
      <email>andres_pacheco19@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrés Pacheco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oriol Roca, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irene Dot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joan R Masclans, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Dot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Caballero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesús Caballero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundació Althaia</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carles Subirà, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Carles Subirà, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mireia Ferreruela, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mireia Ferreruela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gemma Rialp, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gemma Rialp, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arantxa Mas, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Arantxa Mas, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melinda Popoviciu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edgar Cortés, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Trenado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Josep Trenado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalo Hernández, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gonzalo Hernández, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High flow nasal cannula</keyword>
  <keyword>Nasal high flow</keyword>
  <keyword>High flow oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

